Graybug Vision (NASDAQ:GRAY) Shares Down 0.3%

Graybug Vision, Inc. (NASDAQ:GRAYGet Rating)’s share price dropped 0.3% on Friday . The stock traded as low as $3.09 and last traded at $3.09. Approximately 771 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 2,165 shares. The stock had previously closed at $3.10.

Graybug Vision Stock Performance

The firm’s 50 day moving average price is $3.75 and its two-hundred day moving average price is $7.23. The firm has a market cap of $4.85 million, a PE ratio of -0.13 and a beta of 1.20.

Institutional Trading of Graybug Vision

Several hedge funds have recently made changes to their positions in the company. BML Capital Management LLC purchased a new position in shares of Graybug Vision during the 4th quarter worth approximately $618,000. Vanguard Group Inc. boosted its position in shares of Graybug Vision by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 455,572 shares of the company’s stock worth $561,000 after purchasing an additional 23,846 shares during the period. Renaissance Technologies LLC boosted its position in Graybug Vision by 284.8% in the 3rd quarter. Renaissance Technologies LLC now owns 200,492 shares of the company’s stock valued at $189,000 after buying an additional 148,392 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in Graybug Vision in the 1st quarter valued at approximately $125,000. Hedge funds and other institutional investors own 49.94% of the company’s stock.

About Graybug Vision

(Get Rating)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Further Reading

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with's FREE daily email newsletter.